UBC earns high ratings in 2010 late phase market dynamics survey

United BioSource Corporation (UBC) today announced results from an independent survey that examined late phase product development services delivered by 34 contract research organizations and other scientific and medical affairs companies serving the biopharmaceutical industry. The report, titled 2010 Late Phase Market Dynamics and published by Industry Standard Research (ISR), provided data and analysis from a survey that captured information from 149 respondents, representing 95 companies. Survey respondents ranked UBC above all competitors including top 10 contract research organizations on key performance measures, including: 1) overall satisfaction with service providers, 2) willingness to recommend to colleagues or friends; and 3) likelihood to use a service provider again.

"We are gratified to learn from an independent survey that UBC earned high client ratings and that we ranked above our industry's top ten competitors on important measures of customer satisfaction and loyalty," said Ethan Leder, CEO of UBC. "We will continue to work tirelessly to deliver outstanding service when clients choose UBC as their partner for scientific and medical affairs solutions."

"While the large, multi-service brands often dominate awareness in our research, it's not uncommon for more specialized companies to receive higher marks for service quality and that's what we've found in the late phase market," explained Kevin Olson, President, Industry Standard Research. "UBC received high marks for service quality, with about 50 percent of their customers indicating that UBC exceeds their expectations. As much of our research has shown, differentiation is very difficult to come by for drug development service providers but, operationally speaking, UBC appears to be demonstrating excellent service quality on attributes sponsors find important."

SOURCE United BioSource Corporation

www.unitedbiosource.com